Post-injection observation
A 2024 study published in JAMA Ophthalmology found that patients prescribed semaglutide had a higher observed risk of NAION compared with patients using non-GLP-1 medications for diabetes or weight loss
Desde una perspectiva clnica y basada en los ensayos de fase II y los datos preliminares, la eficacia de la retatrutida es superior a cualquier agente farmacolgico previo, con reducciones de peso corporal que oscilan entre el 25% y el 30% en un periodo de 48 semanas
[1] [2] Hers leans harder into brand-name access, with options like the Wegovy Pill and Zepbound KwikPen front and center
However, similar to GLP-1RAs, these agents may induce gastrointestinal adverse effects including anorexia and gastrointestinal discomfort
Research indicates that changes in thymic factors may affect circadian rhythms, impacting cellular and humoral immunity